MicroRNAs are emerging as powerful allies in the fight against cancer, capable of blocking various pathways that enable tumor growth and spread. Andrea Kasinski, a prominent researcher at Purdue University, is at the forefront of this promising field, exploring how modified microRNAs can serve as effective cancer treatments. Her work emphasizes the multifaceted approach of these small RNA segments in targeting multiple genes associated with cancer progression.
The Power of MicroRNAs
Cancer is a complex disease, often fueled by multiple genetic mutations. Traditional therapies typically target single genes, which can lead to resistance as cancer cells evolve. Kasinski highlights that microRNAs offer a strategic advantage by impacting several genes simultaneously. This capability allows for a more robust and resilient therapeutic approach, potentially outpacing conventional treatments.
MicroRNAs, which are short, noncoding RNA molecules, play a crucial role in gene regulation. They manage which genes are expressed and how proteins are synthesized. Cancer cells often exploit these regulatory mechanisms to promote their growth and survival. By understanding the role of microRNAs, researchers can develop novel therapies that disrupt these processes.
Development of MicroRNA-34a
One significant focus of Kasinski’s research is the modified microRNA-34a, which targets and suppresses several cancer-related genes, including MET, CD44, and AXL. This microRNA acts by binding to the RNA transcripts of these genes, preventing their expression and thereby hindering tumor development.
To enhance the efficacy of microRNA-34a, Kasinski’s team has engineered it to possess greater stability within cells compared to its natural counterpart. This modification, combined with a specialized delivery system that selectively targets cancer cells, significantly amplifies its therapeutic potential. The goal is to use microRNA-34a in conjunction with existing cancer treatments, thereby creating a synergistic effect that could effectively curb tumor growth.
LigamiR Therapeutics and Funding Success
To advance her research, Kasinski founded LigamiR Therapeutics, a company dedicated to the commercialization of RNA-based therapies. This venture has secured rights to the intellectual property developed at Purdue, including patents related to microRNA-34a. Recent funding from organizations like the V Foundation and the Dr. Ralph and Marian Falk Medical Research Trust has further propelled her research, particularly for triple-negative breast cancer and ovarian cancer.
Kasinski’s work is a part of Purdue’s One Health initiative, which focuses on the interconnectedness of human, animal, and environmental health. This multidisciplinary approach enhances the relevance and application of her findings in real-world scenarios.
Extracellular Vesicles: A New Frontier
In addition to her work with microRNAs, Kasinski is investigating how cancer cells hijack normal cellular processes. One area of interest is the role of extracellular vesicles—small membrane-bound packages released by cells. While normal cells use these vesicles for communication, cancer cells exploit them to facilitate tumor progression and export harmful RNAs and proteins.
Kasinski’s research aims to uncover new therapeutic avenues by understanding these vesicles better. By targeting their formation and function, it may be possible to disrupt the communication pathways that cancer cells utilize to thrive.
Exploring Epigenetics and Drug Resistance
Another intriguing aspect of Kasinski’s research delves into epigenetics, particularly the role of KMT5C, a protein associated with gene regulation. Her laboratory has found that a reduction in KMT5C levels can activate previously silenced genes, potentially contributing to resistance against non-small cell lung cancer therapies.
This discovery underscores the importance of a holistic approach to cancer treatment. By examining how cancer cells manipulate gene expression and evade therapeutic interventions, researchers can develop strategies that address these challenges more effectively.
The Path Forward
As Kasinski continues to explore the complexities of cancer biology, her research exemplifies the significant potential of microRNAs and innovative therapeutic strategies. By targeting multiple genes and understanding the underlying mechanisms of cancer progression, she aims to contribute to more effective treatment options.
The journey of developing RNA therapeutics is both challenging and promising. Kasinski’s work highlights the necessity of adaptability and creativity in scientific research, often requiring a departure from traditional methods to uncover new solutions.
Key Takeaways
- MicroRNAs can simultaneously target multiple genes, providing a strategic advantage over traditional therapies.
- The modified microRNA-34a shows promise in suppressing cancer-related genes and enhancing treatment efficacy.
-
LigamiR Therapeutics aims to commercialize RNA-based therapies, supported by significant funding and institutional collaboration.
-
Extracellular vesicles represent a novel area for therapeutic intervention, highlighting the adaptive strategies of cancer cells.
-
Investigating epigenetics offers insights into drug resistance, paving the way for innovative treatment approaches.
The potential of microRNAs in cancer therapy is vast, and as researchers like Andrea Kasinski forge ahead, we may soon see transformative changes in how we approach cancer treatment. The integration of advanced RNA technologies with a deeper understanding of cancer biology promises to reshape the landscape of oncology.
Read more → www.purdue.edu